Higgins Rob, Lowe David, Hathaway Mark, Lam For, Kashi Habib, Tan Lam Chin, Imray Chris, Fletcher Simon, Chen Klaus, Krishnan Nithya, Hamer Rizwan, Zehnder Daniel, Briggs David
Transplant Unit, University Hospitals Coventry and Warwickshire, Coventry, West Midlands, United Kingdom.
Transplantation. 2009 Mar 27;87(6):882-8. doi: 10.1097/TP.0b013e31819a6788.
After human leukocyte antigen (HLA) antibody-incompatible transplantation, donor specific and third party HLA antibodies may be found, and their levels fall in a donor-specific manner during the first month. However, these changes have not been previously described in detail.
Donor-specific HLA antibody (DSA) and third-party HLA antibody (TPA) levels were measured using the microbead method in 44 presensitized patients who had renal transplantation.
DSA+TPA fell in the first 4 days after transplantation, and greater falls in DSA indicated absorption by the graft. This occurred for class I (57.8% fall compared with 20.2% for TPA, P<0.0005), HLA DR (63.0% vs. 24.3%, P<0.0004), and for HLA DP/DQ/DRB3-4 (34% vs. 17.5%, P=0.014). Peak DSA levels occurred at a mean of 13 days posttransplant, and they were higher than pretreatment in 25 (57%) patients and lower in 19 (43%) patients (P=ns). The risk of rejection was associated with peak DSA levels; 15 of 25 (60%) patients with DSA at median fluorescence intensity (MFI) more than 7000U experienced rejection, compared with 4 of 7 (57%) patients with peak DSA MFI 2000 to 7000U, and 2 of 12 (17%) patients with peak DSA MFI less than 2000U (P<0.02). DSA levels subsequently fell in a donor specific manner compared to TPA.
DSA levels may change markedly in the first month after antibody incompatible transplantation, and the risk of rejection was associated with higher pretreatment and peak levels.
在人类白细胞抗原(HLA)抗体不相容移植后,可能会发现供体特异性和第三方HLA抗体,且在第一个月内其水平以供体特异性方式下降。然而,此前尚未对这些变化进行详细描述。
采用微珠法检测了44例接受肾移植的致敏患者的供体特异性HLA抗体(DSA)和第三方HLA抗体(TPA)水平。
移植后前4天DSA+TPA下降,DSA下降幅度更大表明被移植物吸收。I类抗原(下降57.8%,而TPA为20.2%,P<0.0005)、HLA DR(63.0%对24.3%,P<0.0004)以及HLA DP/DQ/DRB3-4(34%对17.5%,P=0.014)均如此。DSA峰值水平平均出现在移植后13天,25例(57%)患者的DSA峰值水平高于预处理水平,19例(43%)患者低于预处理水平(P=无统计学意义)。排斥反应风险与DSA峰值水平相关;25例DSA中位荧光强度(MFI)超过7000U的患者中有15例(60%)发生排斥反应,而7例DSA峰值MFI为2000至7000U的患者中有4例(57%),12例DSA峰值MFI低于2000U的患者中有2例(17%)(P<0.02)。与TPA相比,DSA水平随后以供体特异性方式下降。
抗体不相容移植后第一个月内DSA水平可能会显著变化,排斥反应风险与较高的预处理水平和峰值水平相关。